Security key
M47238148
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD)
CUSIP: M47238148
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Ordinary Shares, NIS 1.80 par value per share
- Shares outstanding
- 5,591,387
- Total 13F shares
- 55,876
- Share change
- +11,109
- Total reported value
- $80,439
- Price per share
- $1.44
- Number of holders
- 12
- Value change
- +$15,875
- Number of buys
- 2
- Number of sells
- 5
Report period
Q1 2025
Institutions
12
Top holders
10
GLMD full security history
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Galmed Pharmaceuticals Ltd. SEC filings
Galmed Pharmaceuticals Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M47238148
Recent filing periods:
Top shareholders of GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Allen Baharaff |
13D/G
|
— |
2.6%
|
44,128
|
$60,455 | $0 | 31 Dec 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.45%
|
25,400
|
$81,026 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.22%
|
12,530
|
$39,971 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.12%
|
6,721
|
$21,440 | — | 31 Dec 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
59
|
$188 | — | 31 Dec 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
18
|
$57 | — | 31 Dec 2024 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
16
|
$51 | — | 31 Dec 2024 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
14
|
$45 | — | 31 Dec 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
5
|
$15 | — | 31 Dec 2024 | |
| Allworth Financial LP |
13F
|
Company |
0%
|
2
|
$6 | — | 31 Dec 2024 | |
| ELEVATION WEALTH PARTNERS, LLC |
13F
|
Company |
0%
|
1
|
$4 | — | 31 Dec 2024 | |
| Dogwood Wealth Management LLC |
13F
|
Company |
0%
|
1
|
$3 | — | 31 Dec 2024 |
Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) as of Q1 2025
As of 31 Mar 2025,
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
55,876 shares.
The largest 10 holders included
Schonfeld Strategic Advisors LLC, Virtu Financial LLC, TWO SIGMA SECURITIES, LLC, MORGAN STANLEY, UBS Group AG, SBI Securities Co., Ltd., Federation des caisses Desjardins du Quebec, WELLS FARGO & COMPANY/MN, OSAIC HOLDINGS, INC., and Allworth Financial LP.
This page lists
12
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
11
Q1 2025 holders
12
Holder diff
1
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.